(symptoms of prostate cancer) The Less-Flashy Prostate Cancer Treatment (The Motley Fool)

GTx said the drug was also better than the placebo in all the other objectives except the one that patients probably find most annoying — hot flashes. GTx is still evaluating the hot flash data, which won't be presented until the full data set is made public at a medical meeting. The only safety concern in the trial was an elevated incidence of blood clots, which GTx could address with a warning label that says that patients at high risk of getting blood clots shouldn't take the drug. GTx plans to file a New Drug Application with the Food and Drug Administration by the summer. The unpopular drugmaker — it has only 67 Motley Fool CAPS ratings — is trying to get a little more attention. Next month, it plans to release results from another phase 3 trial testing toremifene to prevent prostate cancer in men with a premalignant lesion called prostatic intraepithelial neoplasia (PIN). read more

Tags: motley, fool, drug, gtx, cancer, , symptoms of prostate cancer